Mayne Pharma Group Ltd (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Ltd (ASX: MYX)
Latest News
⏸️ TMF AMP
ASX 200 flat: NAB raises $3bn and Westpac reveals $1.6bn coronavirus impacts
Share Market News
ASX 200 weekly wrap: Negative oil price breaks ASX's winning streak
Share Market News
These 5 ASX 200 shares were last week's biggest gainers
Share Market News
ASX 200 Weekly Wrap: ASX bulls roar with 4th straight week of gains
Share Gainers
These were the best performing ASX 200 shares last week
⏸️ TMF AMP
ASX 200 update: Big four banks tumble and Transurban's traffic evaporates
⏸️ TMF AMP
ASX 200 jumps 7% on Monday
Share Market News
These ASX shares were last week's biggest gainers
Share Market News
Insiders have been buying Kogan and these ASX shares this week
Share Market News
Why Mayne Pharma, Collins Foods, and Perenti are tumbling lower today
Share Fallers
Why Altium and these other ASX shares fell 20% in February
Share Market News
Crown and these ASX 200 shares just crashed to multi-year lows
Frequently Asked Questions
-
Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.
-
Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
18 Jan 2023 | $0.0272 | 100.00% | Special Cash | 27 Jan 2023 |
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Mayne Pharma Group Ltd
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.
Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market.
MYX Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
18 Apr 2024 | $6.75 | $0.09 | 1.35% | 105,398 | $6.65 | $6.77 | $6.60 |
17 Apr 2024 | $6.66 | $-0.14 | -2.06% | 79,559 | $6.61 | $6.79 | $6.61 |
16 Apr 2024 | $6.80 | $-0.16 | -2.30% | 308,570 | $6.85 | $6.85 | $6.60 |
15 Apr 2024 | $6.96 | $-0.10 | -1.42% | 165,730 | $6.96 | $7.05 | $6.90 |
12 Apr 2024 | $7.06 | $-0.05 | -0.70% | 188,930 | $7.09 | $7.28 | $7.04 |
11 Apr 2024 | $7.11 | $-0.08 | -1.11% | 161,928 | $7.10 | $7.13 | $7.00 |
10 Apr 2024 | $7.19 | $0.01 | 0.14% | 776,748 | $7.11 | $7.25 | $7.03 |
09 Apr 2024 | $7.18 | $0.01 | 0.14% | 165,312 | $7.11 | $7.26 | $7.05 |
08 Apr 2024 | $7.17 | $-0.06 | -0.83% | 117,781 | $7.11 | $7.40 | $7.11 |
05 Apr 2024 | $7.23 | $0.02 | 0.28% | 54,508 | $7.13 | $7.23 | $7.10 |
04 Apr 2024 | $7.21 | $0.12 | 1.69% | 177,200 | $7.05 | $7.21 | $7.00 |
03 Apr 2024 | $7.09 | $-0.16 | -2.21% | 78,831 | $7.11 | $7.24 | $7.04 |
02 Apr 2024 | $7.25 | $0.01 | 0.14% | 114,091 | $7.20 | $7.32 | $7.18 |
28 Mar 2024 | $7.24 | $0.02 | 0.28% | 147,582 | $7.30 | $7.32 | $7.10 |
27 Mar 2024 | $7.22 | $0.37 | 5.40% | 205,009 | $6.82 | $7.22 | $6.82 |
26 Mar 2024 | $6.85 | $0.02 | 0.29% | 158,672 | $6.80 | $6.88 | $6.70 |
25 Mar 2024 | $6.83 | $-0.13 | -1.87% | 169,350 | $6.95 | $7.00 | $6.83 |
22 Mar 2024 | $6.96 | $-0.01 | -0.14% | 109,982 | $6.91 | $6.98 | $6.79 |
21 Mar 2024 | $6.97 | $-0.03 | -0.43% | 199,525 | $7.05 | $7.18 | $6.94 |
20 Mar 2024 | $7.00 | $-0.02 | -0.28% | 155,454 | $7.02 | $7.09 | $6.93 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
08 Dec 2023 | Shawn O'Brien | Issued | 290,554 | $1,699,740 |
Issue of securities. 6,54,657 Rights
|
01 Dec 2023 | Frank Condella | Buy | 7,154 | $38,811 |
On-market trade.
|
25 Oct 2023 | Kathryn MacFarlane | Buy | 18,000 | $69,120 |
On-market trade.
|
24 Oct 2023 | Shawn O'Brien | Buy | 37,041 | $140,917 |
On-market trade.
|
23 Oct 2023 | Ann Custin | Buy | 6,037 | $20,207 |
On-market trade.
|
20 Oct 2023 | Ann Custin | Buy | 6,250 | $20,920 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Frank Condella | Non-Executive DirectorNon-Executive Chairman | May 2018 |
Mr Condella is a US resident has over 30 years of experience in senior executive roles in the global pharmaceutical industry. His operating experience includes Chief Executive Officer of Juniper Pharmaceuticals, a US publicly-listed CDMO and specialty pharmaceutical company, which was subsequently sold to Catalent. Previously he served as Chief Executive Officer of Skyepharma Plc, President of European operations at IVAX (Teva), Chief Executive Officer of Faulding Pharmaceuticals, Vice President of Specialty Care Products at Roche and Vice President and General Manager of the Lederle Standard Products (Pfizer). Mr Condella's previous board experience includes Chairman of Skyepharma Plc until it merged with Vectura, Vice Chairman of Vectura Plc, Independent Director of Prosonix ltd, Independent Director of Fulcrum Pharma plc, Independent Director of Fertin Pharma A/S, Independent Director of Palladio Biosciences Inc and Chairman of the PKD Foundation. He is Chairman of People Commitee.
|
Professor Bruce Gregory Robinson | Non-Executive Director | Aug 2014 |
Mr Robinson is a practising Endocrinologist at Sydney's Royal North Shore Hospital, is Former Dean of University of Sydney's Sydney Medical School. Professor Robinson has been the head of the Cancer Genetics Unit at the Kolling Institute of Medical Research, Royal North Shore Hospital since 1989. Since 2001, Professor Robinson has been Chairman of Hoc Mai Foundation, a major program in medical and health education and exchange with Vietnam. He is a Non-Executive Director of Cochlear Limited, Lorica and QBiotics Group Limited. He is a Board Member of the Woolcock Institute, is Chair of National Health and Medical Research Council and Chair of the Medical Benefits Review Taskforce.Prof Robinson is Chair of the Science, Technology and Medical Committee.
|
Mr Patrick J Blake | Non-Executive Director | Jun 2018 |
Mr Blake is a US resident, has over 30 years of global healthcare industry experience including more than 20 years at McKesson Corporation, one of the healthcare services and information technology companies globally, and more than 10 years at Baxter Healthcare Corporation. Most recently, he was Executive Vice President of McKesson Corporation and Group President of McKesson Technology Solutions which services the health IT needs of hospitals and health systems, payers, physicians, homecare agencies, retail pharmacies and manufacturers, a position he held from 2009 until 2017. Previously, he was President of McKesson Specialty Health, a business focused on the US specialty/biotech sector which was McKesson's business for three years during his leadership. He was also President of Customer Operations for McKesson Pharmaceutical (US) from 2000 to 2006, leading commercial sales and operations for the wholesale distribution of branded, specialty and generic pharmaceuticals and other related products.Mr Blake is a member of the Risk Committee and People Committee.
|
Ms Ann Custin | Non-Executive Director | Mar 2022 |
Ms Custin is a US resident, has almost 40 years of experience in the healthcare sector. Most recently, Ms Custin was Board Director and CFO of Siemens Medical Solutions, a leading medical technology company with EUR20b in revenues. Previously, she was Chief Operating and Financial Officer of Scient'x Group and President and CEO of USA Draeger Medical Systems. Ms Custin is a Non-Executive Director Establishment Labs Holdings Inc (NASDAQ:ESTA).Ms Custin is Chair of the Risk Committee
|
Dr Kathryn MacFarlane | Non-Executive Director | Feb 2022 |
Dr MacFarlane is a US resident, has more than 30 years of experience in the pharmaceutical industry. She is currently Founder and Managing Partner of SmartPharma LLC, offering commercial and strategic consulting services to pharmaceutical companies. Previously, she was Chief Commercial Officer at Agile Therapeutics, Vice President Women's Health Care Marketing, Sales and New Product Planning at Warner Chilcott and Senior Director of Marketing at ParkeDavis.Dr MacFarlane is a member of the of the Science, Technology and Medical Committee.
|
Mr David Petrie | Non-Executive Director | Sep 2022 |
Mr Petrie is an accomplished M&A executive with over 30 years of advisory experience in public and private mergers and acquisitions, capital management and debt and equity raisings. He is currently Principal at Stratford Advisory Group, an independent corporate and financial advisory firm. Previously, he spent 23 years at Merrill Lynch/Bank of America including Managing Director and Head of Investment Banking Melbourne. He has worked on more than 100 transactions across a range of market sectors including healthcare.Mr Petrie is a member of the Risk and People Committee.
|
Mr Shawn Patrick O'Brien | Chief Executive OfficerManaging Director | Oct 2022 |
Mr O'Brien has more than 35 years of global pharmaceutical industry experience building enterprises. He was a founding partner of Key BioPharma Partners providing advice to life science companies and capital providers. He was previously the Chairman and CEO of Genomind Inc., a personalised mental health platform company, and CEO of publicly listed Cipher Pharmaceuticals Inc., a specialty pharmaceutical company with a portfolio of commercial stage dermatology products. He has also been President and CEO of three private biotechs including AltheRx Pharmaceuticals, Profectus BioSciences and Solstice Neurosciences. Mr O'Brien held multiple senior leadership roles at AstraZeneca, one of the global pharmaceutical companies. At AstraZeneca he was responsible for key brands such as FASLODEX, SYMBICORT, PULMICORT and SEROQUEL which all became billion-dollar brands.
|
Ms Anne Nicole Lockwood | Non-Executive Director | Nov 2023 |
--
|
Ms Laura Loftus | Company Secretary | Mar 2020 |
-
|
Laura Loftus | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Citicorp Nominees Pty Limited | 10,761,314 | 12.90% |
HSBC Custody Nominees (Australia) Limited | 7,245,424 | 8.70% |
J P Morgan Nominees Australia Pty Limited | 6,792,556 | 8.10% |
Mr Bruce Mathieson And Related Entities | 5,292,066 | 6.30% |
Estetra Srl <No 1 Account> | 4,221,815 | 5.10% |
HSBC Custody Nominees (Australia) Limited <Gsco Customers A/C> | 3,369,950 | 4.00% |
Solium Nominees (Australia) Pty Ltd <Bare Allocated A/C> | 2,359,715 | 2.80% |
National Nominees Limited | 2,052,695 | 2.50% |
Bnp Paribas Noms Pty Ltd <Drp> | 1,954,119 | 2.30% |
Gft 2 Co Pty Limited <Gft 2 A/C> | 1,295,569 | 1.60% |
Ivl Group Pty Ltd | 800,000 | 1.00% |
Vivnat (Curtin) Pty Ltd | 750,000 | 0.90% |
R & R Corbett Pty Ltd <R C Corbett Family A/C> | 522,028 | 0.60% |
Y S Chains Pty Ltd | 500,000 | 0.60% |
Retzos Executive Pty Ltd <Retzos Executive S/Fund A/C> | 465,000 | 0.60% |
Mr Kon Tzimokas | 400,000 | 0.50% |
Wal Assets Pty Ltd <The La Wilson Property A/C> | 354,500 | 0.40% |
Birbal Investments Pty Ltd | 300,000 | 0.40% |
Mr Yunsong Zhang | 300,000 | 0.40% |
Belgravia Strategic Equities Pty Ltd | 295,250 | 0.40% |